

1/22

PTO/SB/92 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

## Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on 03/17/05  
Date

*Denise Bierlein*

Signature

Denise Bierlein

Type or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Application No: 10/762,395

Filing Date: January 22, 2004

Title: Use of Post-Transcriptional Gene Silencing For Identifying Nucleic Sequences That Modulate the Function of a Cell

Attorney Docket: 26788-009

- Supplemental Information Disclosure Statement
- PTO/SB/08B Form with Copies of Non-Patent Literature Documents
- Transmittal Form
- Receipt Card



Please type a plus sign (+) inside this box



PTO/SB/21(08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number 10/762,395

Filing Date January 22, 2004

First Named Inventor Tony Giordano

Group Art Unit 1645

Examiner Name Unknown

Total Number of Pages in This Submission

73

Attorney Docket Number

26788-009

### ENCLOSURES (check all that apply)

☐ Fee Transmittal Form

☐ Fee Attached

☐ Amendment / Response

☐ After Final

☐ Affidavits/declaration(s)

☐ Extension of Time Request

☐ Express Abandonment Request

☒ Supplemental Information  
Disclosure Statement

☐ Certified Copy of Priority  
Document(s)

☐ Response to Missing Parts/  
Incomplete Application

☐ Response to Missing  
Parts under 37 CFR  
1.52 or 1.53

☐ Assignment Papers  
(for an Application)

☐ Drawing(s)

☐ Licensing-related Papers

☐ Petition

☐ Petition to Convert to a  
Provisional Application

☐ Power of Attorney, Revocation  
Change of Correspondence Address

☐ Terminal Disclaimer

☐ Request for Refund

☐ CD, Number of CD(s) \_\_\_\_\_

☐ After Allowance Communication  
to Group

☐ Appeal Communication to Board of  
Appeals and Interferences

☐ Appeal Communication to Group  
(Appeal Notice, Brief, Reply Brief)

☐ Proprietary Information

☐ Status Letter

☒ Other Enclosure(s) (please  
identify below):

- PTO/SB/08B Form with  
Copies of Non Patent  
Literature Documents
- Certificate of Mailing
- Receipt Card

Remarks

### SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm

or  
Individual name

Kathleen W. Geiger, Registration No. 35,880

Signature

*Kathleen W. Geiger*

Date

### CERTIFICATE OF MAILING

I hereby certify that this correspondence is being sent via first class mail to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name

Denise Bierlein

Signature

*Denise Bierlein*

Date

03/17/05

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Tony Giordano et al.

Group Art Unit: 1645

Application No.: 10/762,395

Examiner: Unknown

Filed: January 22, 2004

Attorney Docket No.: 26788-009

Title: Use of Post-Transcriptional Gene Silencing For Identifying Nucleic Sequences That Modulate the Function of a Cell

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Listed on the accompanying PTO/SB/08B Form are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. 1.56, 1.97 and 1.98.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.


This statement should not be construed as a representation that an exhaustive search has been made, or that there does not exist information more material to the examination of the present patent application. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will review art of record in all 35 U.S.C. 120 priority documents.

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO/SB/08B Form, and to indicate in the official file wrapper of this patent application that the documents have been considered.

Applicants do not believe that any fee is due in accordance with the filing of this Supplemental Information Disclosure Statement. However, should there be a fee due that is unaccounted for the Commissioner is hereby authorized to charge any fee deficiency, or credit any overpayment, to Deposit Account No. 501447 (Potter Anderson & Corroon LLP).

Respectfully submitted,

By:

  
Kathleen W. Geiger  
Reg. No. 35,880

Telephone: (302) 984-6075

Facsimile: (302) 658-1192

Date: 03/17/05



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/762,395
Filing Date	January 22, 2004
First Named Inventor	Tony Giordano
Art Unit	1645
Examiner Name	Unknown
Attorney Docket Number	26788-009

Sheet 1 of 1

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		GOHLA ET AL., A Rapid and Sensitive Fluorometric Screening Assay Using YO-PRO-1 to Quantify Tumour Cell Invasion...., Clin. Exp. Metastasis, 1996, Vol. 14, No. 5, pp. 451-458.	
		KOHN ET AL., Molecular Insights Into Cancer Invasion: Strategies for Prevention and Intervention, Perspectives in Cancer Research, 1995, pp. 1856-1862.	
		SASAKI ET AL., Identification of Anti-Invasive but Noncytotoxic Chemotherapeutic Agents Using the ...., Cancer Research Techniques, 1998, Vol. 24, No. 6, pp. 1038-1044.	
		GATZ, CHRISTIANE, Novel Inducible/Repressible Gene Expression Systems, Methods in Cell Biology, Chapter 30, 1995, Vol. 50, pp. 411-424.	
		LIU ET AL., Lac/Tet Dual-Inducible System Functions in Mammalian Cell Lines, Short Technical Reports, BioTechniques, April 1998, Vol. 24, No. 4, pp. 624-632.	
		HABU ET AL., Development of an HIV-1-Dependent Expression Vector With the Cre/loxP System, Nucleic Acids Symposium Series, 1999, No. 42, pp. 295-296.	
		FULKS ET AL., Sequence Analysis of the Inversion Region Containing the Pilin Genes of Moraxella Bovis, Journal of Bacteriology, Jan. 1990, Vol. 172, No. 1, pp. 310-316.	
		LANZOV ET AL., Recombinational Mechanism of Precise Excision of IS50 Mobile Element in...., Konstantinov Nuclear Physics Institute, 1994, Vol. 28, No. 3, pp. 563-573.	

Examiner Signature	Date Considered
-----------------------	--------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.